Disease · MONDO_0001247
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PH94B vs Placebo: Proportions (%) of CGI-I Responders in PH94B-treated and Placebo-treated Groups at the End of Visit 3 (Treatment) | 34 of 111 | 36 of 112 | 223 | NCT04754802 | Trial comparisons |
| PH94B vs Placebo: deaths from any cause | 0 of 111 | 0 of 112 | 223 | NCT04754802 | Trial comparisons |
| PH94B vs Placebo: serious adverse events | 0 of 111 | 0 of 112 | 223 | NCT04754802 | Trial comparisons |
| D-cycloserine-augmented CBT vs Placebo-augmented CBT: serious adverse events | 0 of 87 | 0 of 82 | 169 | NCT00515879 | Trial comparisons |
| JNJ-42165279 25 mg vs Placebo: deaths from any cause | 0 of 74 | 0 of 75 | 149 | NCT02432703 | Trial comparisons |
| JNJ-42165279 25 mg vs Placebo: serious adverse events | 2 of 74 | 0 of 75 | 149 | NCT02432703 | Trial comparisons |
| PH94B vs Placebo: Proportions (%) of CGI-I Responders in PH94B-treated and Placebo-treated Groups at the End of Visit 3 (Treatment) | 26 of 70 | 15 of 71 | 141 | NCT05011396 | Trial comparisons |
| CERC-501 vs Placebo: deaths from any cause | 0 of 45 | 0 of 44 | 89 | NCT02218736 | Trial comparisons |
| CERC-501 vs Placebo: serious adverse events | 0 of 45 | 0 of 44 | 89 | NCT02218736 | Trial comparisons |
| SPD503 vs PLACEBO: serious adverse events | 0 of 62 | 0 of 21 | 83 | NCT01470469 | Trial comparisons |
| Paroxetine Continuation vs Paroxetine With CBT Augmentation: deaths from any cause | 0 of 29 | 0 of 32 | 61 | NCT00074802 | Trial comparisons |
| Paroxetine Continuation vs Paroxetine With CBT Augmentation: serious adverse events | 1 of 29 | 0 of 32 | 61 | NCT00074802 | Trial comparisons |
| Oxytocin vs Placebo: serious adverse events | 0 of 27 | 0 of 27 | 54 | NCT01856530 | Trial comparisons |
| BHV-0223 (Sublingual Riluzole) vs Placebo: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT03017508 | Trial comparisons |
| BHV-0223 (Sublingual Riluzole) vs Placebo: serious adverse events | 0 of 22 | 0 of 22 | 44 | NCT03017508 | Trial comparisons |
| Sugar Pill vs Yohimbine Hydrochloride: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT00958880 | Trial comparisons |
| Ketamine Infusion on Day 0 or Day 28 vs Saline Infusion on Day 0 or Day 28: deaths from any cause | 0 of 18 | 0 of 17 | 35 | NCT02083926 | Trial comparisons |
| Ketamine Infusion on Day 0 or Day 28 vs Saline Infusion on Day 0 or Day 28: serious adverse events | 0 of 18 | 0 of 17 | 35 | NCT02083926 | Trial comparisons |
| Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2) vs Duloxetine 120mg/Day for 18 Weeks (Phase 2): serious adverse events | 2 of 13 | 0 of 15 | 28 | NCT00114127 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001247/comparisons